Apomorphine in the treatment of Parkinson disease and other movement disorders

被引:0
作者
Gunzler, Steven A. [1 ]
机构
[1] Case Western Reserve Univ, Sch Med, Univ Hosp,Movement Disorders Ctr, Case Med Ctr,Neurol Inst, Cleveland, OH 44106 USA
关键词
apomorphine; dopamine agonist; movement disorders; Parkinson disease; RESTLESS LEGS SYNDROME; DEEP BRAIN-STIMULATION; NEUROLEPTIC MALIGNANT SYNDROME; TERM-FOLLOW-UP; SUBCUTANEOUS APOMORPHINE; DOUBLE-BLIND; MOTOR FLUCTUATIONS; HUNTINGTONS-CHOREA; L-DOPA; DOPAMINERGIC RESPONSIVENESS;
D O I
10.1517/14656560902828344
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Apomorphine, a medication that has been studied intensively over the years, is available in the US as intermittent subcutaneous injections for treatment of 'off' motor states in Parkinson disease. Objective: The clinical literature is summarized with particular focus on randomized controlled studies of apomorphine in the treatment of Parkinson disease. Methods: After reviewing the pharmacologic properties of apomorphine, the English language literature is summarized with particular attention on articles resulting from a Medline search of apomorphine and Parkinson disease limited to randomized controlled studies. Other formulations and indications for treatment of movement disorders are also discussed. Results/conclusion: Subcutaneous apomorphine is well tolerated when co-administered with trimethobenzamide or domperidone premedication. it has a unique efficacy as a 'rescue' medication owing to its rapid onset of action. Subcutaneous infusion, although not an approved route of administration in the US, provides more continuous dopaminergic stimulation and, therefore, ameliorates dyskinesia and motor fluctuations.
引用
收藏
页码:1027 / 1038
页数:12
相关论文
共 50 条
  • [21] Treatment of Visual Disorders in Parkinson Disease
    Savitt, Joseph
    Mathews, Michaela
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2018, 20 (08)
  • [22] Apomorphine in the treatment of Parkinson's disease
    Dressler, D
    NERVENARZT, 2005, 76 (06): : 681 - +
  • [23] Sublingual apomorphine in treatment of Parkinson's disease: a review
    Hislop, Jennifer
    Margolesky, Jason
    Shpiner, Danielle S.
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2024, 134 (05) : 474 - 480
  • [24] An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease
    Mueller, Thomas
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (14) : 1659 - 1665
  • [25] Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
    Borkar, Nrupa
    Mu, Huiling
    Holm, Rene
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 13 (06) : 507 - 517
  • [26] Genetic risk variants in Parkinson's disease and other movement disorders
    Brockmann, K.
    Lohmann, K.
    NERVENARZT, 2017, 88 (07): : 713 - 719
  • [27] Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management
    Antonini, Angelo
    Tolosa, Eduardo
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (06) : 859 - 867
  • [28] Management of psychiatric disorders in Parkinson's disease Neurotherapeutics-Movement Disorders Therapeutics
    Weintraub, Daniel
    NEUROTHERAPEUTICS, 2020, 17 (04) : 1511 - 1524
  • [29] Placebo and Nocebo Responses in Other Movement Disorders Besides Parkinson's Disease: How Much Do We Know?
    Ferreira, Joaquim J.
    Trenkwalder, Claudia
    Mestre, Tiago A.
    MOVEMENT DISORDERS, 2018, 33 (08) : 1228 - 1235
  • [30] Sleep Disorders in Parkinson Disease
    Stefani, Ambra
    Hoegl, Birgit
    SLEEP MEDICINE CLINICS, 2021, 16 (02) : 323 - 334